文献速递银屑病与炎症性皮肤病

拟议阿达木单抗生物类似药GP2017治疗银屑病的III期随机研究:多次转换的影响

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches.
PubMed 文献 · Br J Dermatol · 2018-07-15

这项51周双盲III期研究将活动性中重度斑块状银屑病患者随机分配至GP2017组(n=231)或参照阿达木单抗组(n=234),第17周再随机分为转换组(n=126)与继续组(n=253)。第16周PASI 75应答率两组分别为66.8%和65.0%(95%CI -7.46至11.15),证实等效;多次转换对疗效、安全性和免疫原性无可检测影响。

要点

  • GP2017与参照阿达木单抗在第16周PASI 75应答率分别为66.8%和65.0%,95%CI -7.46至11.15,证实等效。
  • 第17至51周转换组与继续组PASI改善相似,未报告转换后超敏反应。
  • 两组在第16周及第17至51周转换组与继续组间无相关安全性或免疫原性差异。

核心结论

  • 在证实GP2017与参照阿达木单抗生物类似性后,GP2017与参照阿达木单抗间最多四次转换对疗效、安全性或免疫原性无可检测影响。

研究设计与样本

  • 51周双盲III期研究,活动性、临床稳定、中度至重度斑块状银屑病成人患者随机分配至GP2017组(n=231)或参照阿达木单抗组(n=234),第0周皮下注射80 mg,自第1周起每两周40 mg。
  • 第17周患者再随机分为转换组(n=126)或继续组(n=253)。

主要发现

  • 第16周达到PASI 75的患者比例GP2017组为66.8%,参照阿达木单抗组为65.0%,差异95%CI -7.46至11.15。
  • 连续PASI自基线至第16周变化GP2017组为-60.7%,参照阿达木单抗组为-61.5%,差异95%CI -3.15至4.84。
  • PASI随时间改善,第16周时治疗组间相似,第17至51周转换组与继续组间相似。
  • 第16周GP2017与参照阿达木单抗间、第17至51周转换组与继续组间无相关安全性或免疫原性差异。
  • 转换后未报告对阿达木单抗的超敏反应。

关键数值与推荐

  • 主要终点为第16周达到PASI 75的患者,若两组PASI 75差异的95%CI在±18%内则确认等效。
  • 关键次要终点为连续PASI自基线至第16周的变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adalimumab is used to treat several inflammatory diseases, including plaque psoriasis. GP2017 is a proposed adalimumab biosimilar. OBJECTIVES: To assess the impact of multiple switches between GP2017 and reference adalimumab (ref-ADMB) following the demonstration of equivalent efficacy and similar safety and immunogenicity, in adult patients with active, clinically stable, moderate-to-severe plaque psoriasis. METHODS: This 51-week double-blinded, phase III study randomly assigned patients to GP2017 (n = 231) or ref-ADMB (n = 234) 80 mg subcutaneously at week 0, then 40 mg biweekly from week 1. At week 17, patients were rerandomized to switch (n = 126) or continue (n = 253) treatment. The primary end point was patients achieving ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75) at week 16, with equivalence confirmed if the 95% confidence interval (CI) for the difference in PASI 75 between treatments was ± 18%. The key secondary end point was the change from baseline to week 16 in continuous PASI. Other end points were PASI over time; PASI 50, 75, 90 and100; pharmacokinetics; safety; tolerability and immunogenicity for the switched and continued treatment groups. RESULTS: Equivalent efficacy between GP2017 and ref-ADMB was confirmed for the primary (66·8% and 65·0%, respectively; 95% CI -7·46 to 11·15) and key secondary end points (-60·7% and -61·5%, respectively; 95% CI -3·15 to 4·84). PASI improved over time and was similar between treatment groups at week 16, and the switched and continued groups from weeks 17 to 51. There were no relevant safety or immunogenicity differences between GP2017 and ref-ADMB at week 16, or the switched and continued groups from weeks 17 to 51. No hypersensitivity to adalimumab was reported upon switching. CONCLUSIONS: Following the demonstration of GP2017 biosimilarity to ref-ADMB, switching up to four times between GP2017 and ref-ADMB had no detectable impact on efficacy, safety or immunogenicity.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Blauvelt A, Lacour JP, Fowler JF, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018. PMID: 29917226. doi:10.1111/bjd.16890

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。